News Bright Minds Biosciences Inc.

Equities

DRUG

CA10919W4056

Biotechnology & Medical Research

Delayed Canadian Securities Exchange Other stock markets 16:40:42 23/01/2026 GMT			5-day change	1st Jan Change
120.66 ^CAD	-2.76%		-1.81%	+9.26%

01-09	Bright Minds Biosciences Closes its US$175 Million Public Offering	MT
01-09	Bright Minds Biosciences Closes $175.1 Million Stock Offering	MT

01-09	Bright Minds Biosciences Closes its US$175 Million Public Offering	MT
01-09	Bright Minds Biosciences Closes $175.1 Million Stock Offering	MT
01-09	Bright Minds Biosciences Announces Closing of US$175 Million Public Offering	GL
01-08	Bright Minds Biosciences Prices $175 Million Stock Offering	MT
01-08	Bright Minds Biosciences announces pricing of upsized US$175 million public offering of common stock at $90.00 per share	RE
01-08	Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock	AQ
01-06	Bright Minds Biosciences Launches US$100 Million Public Offering	MT
01-06	Bright Minds Biosciences Launches $100 Million Public Offering	MT
01-06	Bright Minds Biosciences Inc. Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies	CI
01-06	Bright Minds Biosciences Announces Launch of US$100 Million Public Offering	AQ
01-06	Bright Minds Biosciences Says Phase 2 Trial Results of BMB-101 Show 'Robust' Reduction in Seizure	MT
01-06	Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)	AQ
01-05	Bright Minds to announce topline results for BMB-101 phase 2 trial on Jan 6	RE
01-05	Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026	AQ
12-23	Bright Minds Biosciences Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
11-25	Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting	AQ
11-17	Bright Minds Biosciences Inc. Expands Scientific Advisory Board	CI
11-17	Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)	AQ
11-06	Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH	AQ
11-06	Bright Minds Biosciences Inc. Initiates New Prader-Willi Syndrome Program	CI
30/10/25	Bright Minds Biosciences to Present at Upcoming Conferences	AQ
22/09/25	Bright Minds Biosciences Inc.(NasdaqCM:DRUG) added to S&P Global BMI Index	CI
05/09/25	Bright Minds Biosciences Enters Deal for $100 Million At-The-Market Offering	MT
05/09/25	BRIGHT MINDS BIOSCIENCES ANNOUNCES AT-THE-MARKET OFFERING	AQ
04/09/25	Sector Update: Health Care Stocks Rise Late Afternoon	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Bright Minds Biosciences Inc.

Equities

DRUG

CA10919W4056

Biotechnology & Medical Research

Filters